Lung Cancer Trial, Recruiting (NCT06075524)

Lung Cancer Trial, Recruiting NCT06075524 Sponsor: Mayo Clinic Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06075524 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with an advanced or late-stage cancer (locally advanced, regionally advanced, or Stage IV), confirmed by a tissue sample (biopsy)
Your doctor has decided that a type of immunotherapy drug called an anti-PD-1 or anti-PD-L1 treatment is appropriate for you (having had this type of immunotherapy before is allowed)
You are able to understand what the study involves, including its requirements, risks, and possible discomforts
You are willing to have blood samples taken at specific points during the study
You are able and willing to sign a consent form agreeing to take part

Who may not be able to join:

You are unable to understand the consent form or are unlikely to be able to follow the study's requirements
You are currently receiving any other cancer treatments or participating in another experimental treatment study (other than the anti-PD-1/anti-PD-L1 immunotherapy mentioned above)
You are pregnant, currently breastfeeding, or are capable of becoming pregnant and are not willing to use adequate birth control during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06075524

Sponsor: Mayo Clinic

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

More information: https://clinicaltrials.gov/study/NCT06075524

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 18 years of age or older
You have been diagnosed with an advanced or late-stage cancer (locally advanced, regionally advanced, or Stage IV), confirmed by a tissue sample (biopsy)
Your doctor has decided that a type of immunotherapy drug called an anti-PD-1 or anti-PD-L1 treatment is appropriate for you (having had this type of immunotherapy before is allowed)
You are able to understand what the study involves, including its requirements, risks, and possible discomforts
You are willing to have blood samples taken at specific points during the study
You are able and willing to sign a consent form agreeing to take part

Who may not be able to join:

You are unable to understand the consent form or are unlikely to be able to follow the study's requirements
You are currently receiving any other cancer treatments or participating in another experimental treatment study (other than the anti-PD-1/anti-PD-L1 immunotherapy mentioned above)
You are pregnant, currently breastfeeding, or are capable of becoming pregnant and are not willing to use adequate birth control during the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

15 June 2015

Est. completion

31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Role of Bim for monitoring disease status during anti-PD-1 therapy; Mechanisms of resistance to anti-PD-1 blockade; Quantify and modulate levels of NKG7 mRNA in CD8+ T cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov